NIAID starts Phase I/II of Chikungunya vaccine

NIH's National Institute of Allergy and Infectious Diseases (NIAID) began a Phase I/II trial of the Chikungunya fever vaccine (MV-CHIKV vaccine) from Themis Bioscience GmbH (Vienna, Austria) to prevent Chikungunya virus infection. The double-blind, U.S. trial is evaluating CHIKV serum antibody geometric mean titer (GMT), anti-CHIKV antibody responses and safety in 180 healthy volunteers. Subjects will receive placebo or 5x10⁴ or 5x10⁵ TCID50 intramuscular MV-CHIKV vaccine on day 1 and then on days 29, 85 or 169...